- Home
- NGNE vs SOR Comparison
NGNE vs SOR Comparison
Compare NGNE & SOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- SOR
- Stock Information
- Founded
- NGNE 2003
- SOR 1968
- Country
- NGNE United States
- SOR United States
- Employees
- NGNE N/A
- SOR N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- SOR Investment Managers
- Sector
- NGNE Health Care
- SOR Finance
- Exchange
- NGNE Nasdaq
- SOR Nasdaq
- Market Cap
- NGNE 325.3M
- SOR 358.4M
- IPO Year
- NGNE N/A
- SOR N/A
- Fundamental
- Price
- NGNE $22.72
- SOR $43.83
- Analyst Decision
- NGNE Strong Buy
- SOR
- Analyst Count
- NGNE 7
- SOR 0
- Target Price
- NGNE $41.86
- SOR N/A
- AVG Volume (30 Days)
- NGNE 216.3K
- SOR 16.2K
- Earning Date
- NGNE 08-08-2025
- SOR 01-01-0001
- Dividend Yield
- NGNE N/A
- SOR 7.24%
- EPS Growth
- NGNE N/A
- SOR N/A
- EPS
- NGNE N/A
- SOR 6.50
- Revenue
- NGNE $925,000.00
- SOR N/A
- Revenue This Year
- NGNE N/A
- SOR N/A
- Revenue Next Year
- NGNE N/A
- SOR N/A
- P/E Ratio
- NGNE N/A
- SOR $6.41
- Revenue Growth
- NGNE N/A
- SOR N/A
- 52 Week Low
- NGNE $6.88
- SOR $36.41
- 52 Week High
- NGNE $74.49
- SOR $42.75
- Technical
- Relative Strength Index (RSI)
- NGNE 60.64
- SOR 57.63
- Support Level
- NGNE $20.80
- SOR $41.98
- Resistance Level
- NGNE $23.88
- SOR $44.68
- Average True Range (ATR)
- NGNE 1.44
- SOR 0.93
- MACD
- NGNE 0.09
- SOR -0.06
- Stochastic Oscillator
- NGNE 72.83
- SOR 59.32
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.